The U.S. FDA recently approved Attruby (acoramidis) for adults with ATTR-CM to reduce cardiovascular death, hospitalization. A study highlights the significant HCRU and costs associated with ATTR-CM. Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis. A case study highlights the importance of avoiding anchoring bias in the diagnosis of cardiac amyloidosis. The diagnosis of AL amyloidosis requires a high index of suspicion to render a prompt diagnosis and appropriate treatment. A study further supports the efficacy of acoramidis in the treatment of people with ATTR-CM. People with amyloidosis have a significantly higher prevalence of atrial fibrillation. An AI model for detecting ATTR-CA yields solid diagnostic results. On average, the readability of patient educational materials on cardiac amyloidosis fails to meet NIH standards. A deep-learning model is able to detect ATTR-CM with robust efficacy. Practical strategies are needed in health centers to ensure patients with ATTRv receive optimal care. Artificial intelligence-enhanced ECG models can effectively detect cardiac amyloidosis. Individuals with transthyretin amyloid cardiomyopathy who have clonal hematopoiesis have an increased risk of mortality.